



Attorney's Docket No. 033136-18

TECH CENTER 1600/2900

SEP 26 2001

RECEIVED

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Anthony E. Bolton et al.

Application No.: 09/871,146

Filed: May 25, 2001

For: APOPTOTIC ENTITIES FOR USE IN
TREATMENT OF
NEUROGENERATIVE AND OTHER
NEUROLOGICAL DISORDERS

Group Art Unit: 1614

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By: Leslie J. Boley
Leslie J. Boley
Registration No. 41,490

Date: September 21, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Inventor Patent Application of)

Anthony E. Bolton et al.)

Application No.: 09/871,146)

Filed: May 25, 2001)

For: APOPTOTIC ENTITIES FOR USE IN)
TREATMENT OF)
NEUROGENERATIVE AND OTHER)
NEUROLOGICAL DISORDERS)

Group Art Unit: 1614

Examiner: Unassigned

TECH CENTER 1600/2900

SEP 26 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

Publications

Bliss, T.V.P., et al., "A synaptic model of memory: long-term potentiation in the hippocampus," *Nature*, **361**:31-39 (1993).

Bombeli, T., et al., Apoptotic Vascular Endothelial Cells Become Procoagulant," *Blood*, **89**:2429-2442 (1997).

Buttke and Sandstrom, et al., "Oxidative Stress As a Mediator of Apoptosis," *Immunology Today*, **15**:7-10 (1994).

Fadok, V.A., et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages," *Journal of Immunology*, **148**:2207-2216 (1992).

Fadok, V.A. et al., "A receptor for phosphatidylserine-specific clearance of apoptotic cells," *Nature*, **405**:85-90 (2000).

Gavrieli, Y., et al., "Identification of Programmed Cell Death In Situ via Specific Labelling of Nuclear DNA Fragmentation," *J. of Cell Biology*, **119**:493-501 (1992).

Griffin, W.S.T., et al., "Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer disease," *Proceedings of the National Academy of Sciences USA*, **86**:7611-7615 (1989).

Guijarro, C., et al., "3-Hydroxy-3 Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle in Culture," *Circulation Research*, **83**:490-500 (1998).

Kerr et al., "Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics," *British Journal of Cancer*, **26**:239-257 (1991).

Kondo, et al., "Lymphocyte Function-Associated Antigen-1 is Required for Maximum Elicitation of Allergic Contact Dermatitis," *Br. J. Dermatol.* **131**:354-359 (1994).

Kondo, et al., "Interleukin-10 Inhibits the Elicitation Phase of Allergic Contact Hypersensitivity," *The Journal of Investigative Dermatology*, **103**:811-814 (1994).

Loo, D. T. and Rillema, J.R., "Measurement of Cell Death," *Methods in Cell Biology*, **57**:251-264 (1998).

Mogi, M., et al., "Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease," *Neuroscience Letters*, **211**:13-16 (1996).

Murray, C.A. et al., "Evidence that increase hippocampal expression of the cytokine interleukin-1 β is a common trigger for age and stress-induced impairments in long-term potentiation," *Journal of Neuroscience*, **18**:2974-2981 (1998).

Salvioli, S., et al., "JC-1, but not DiOC₆(3) or Rhodamine 123, is a Reliable Fluorescent Probe to Assess $\Delta\Psi$ Changes in Intact Cells: Implications For Studies on Mitochondrial Functionality During Apoptosis," *FEBS Letters* **411**:77-82 (1997).

Susin, S.A., "Mitochondrial Release of Caspase-2 and -9 During the Apoptotic Process," *Journal of Experimental Medicine*, **189**:381-394 (1994).

Suzuki, Y., "Cell Death Phagocytosis, and Neurogenesis in Mouse Olfactory Epithelium and Vomeronasal Organ After Colchicine Treatment," *Annals of the New York Academy of Sciences*, **855**:252-254 (1998).


Teiger, E., "Apoptosis in Pressure Overload-Induced Heart Hypertrophy in the Rat," *Journal of Clinical Investigation*, **97**:2891-2897 (1996).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b)

To assist the Examiner, the listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Leslie J. Boley
Registration No. 41,490

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: September 21, 2001